FIELD: medicine; oncology.
SUBSTANCE: group of inventions relates to medicine, namely to oncology, in particular to a method for the treatment of lung tumor using taxan particles. The method includes intrapulmonary administration to a subject with lung cancer by means of nebulizer of the effective amount of a composition in the form of a suspension, containing taxan particles and a pharmaceutically acceptable carrier. Taxan includes paclitaxel or its pharmaceutically acceptable salt. Taxan particles contain at least 95% of taxan, have an average size (quantitative) from 0.4 mcm to 3 mcm, specific surface area (SSA) from 27 m2/g to 60 m2/g. The suspension is converted to aerosol for the administration. Formed aerosol drops have a mass median aerodynamic diameter (MMAD) from 0.5 mcm to 6 mcm. The use of a composition containing taxan particles for the treatment of lung tumor is also proposed.
EFFECT: inventions lead to significantly more long-lasting retention of taxan in the lungs, in particular long-lasting period of action is at least 4 weeks.
21 cl, 54 dwg, 15 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS OF TREATING SOLID TUMORS | 2017 |
|
RU2737934C2 |
COMBINATIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY | 2013 |
|
RU2673805C2 |
COMBINATION AND METHODS FOR INTRODUCING THERAPEUTIC AGENTS AND COMBINED THERAPY | 2006 |
|
RU2452482C2 |
COMBINATIONS AND METHODS FOR THERAPEUTIC AGENTS INTRODUCTION AND COMBINED THERAPY | 2012 |
|
RU2632103C2 |
COMBINED THERAPY WITH COMPOSITIONS OF TAXANE NANOPARTICLES AND HEDGEHOG INHIBITORS | 2010 |
|
RU2561055C2 |
TAXAN PARTICLES AND THEIR APPLICATION | 2016 |
|
RU2750163C2 |
ANTI-ANGIOGENESIS THERAPY USED FOR TREATING BREAST CANCER | 2009 |
|
RU2531948C2 |
METHODS FOR BLADDER CANCER TREATMENT | 2011 |
|
RU2621640C2 |
METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
POLYGLUTAMATE-AMINO ACID CONJUGATES AND METHODS | 2006 |
|
RU2472812C2 |
Authors
Dates
2022-06-09—Published
2018-06-13—Filed